Bought DSCI at $10 and it's been doing very well. Market cap is tiny. Undervalued imo based on the potential. Just had good phase 2 results for their diabetic foot ulcers. phase 3 trials are estimated to cost about $15 million. with just a little dilution, they could fund them themselves and not have to give a way a piece of the pie to a partner. they are already generating revenues of around $40 million that is growing.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.